Skip to main content
. 2021 Sep 17;40(1):72–82. doi: 10.1200/JCO.21.01332

FIG 1.

FIG 1.

Study design. aDropouts include death, progression, adverse events, and investigator's decision. CR, complete remission; ECOG, Eastern Cooperative Oncology Group; FOLFOX, fluorouracil, folinic acid, and oxaliplatin; FU/FA, fluorouracil and folinic acid; mCRC, metastatic colorectal cancer; PD, progressive disease; PFS, progression-free survival; Pmab, panitumumab; PR, partial remission; R, random assignment; SD, stable disease; WT, wild type.